Answer
The UK licence is based on combined platelet inhibition after coronary intervention for acute coronary syndrome. Both treatments contribute to clot prevention, while also increasing bleeding risk.
Sources for this answer
- Prasugrel 10 mg film-coated tabletsemc · SmPC Current selected SmPC · Version 1